Meeting
2013 ASCO Annual Meeting
Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer.
Authors
Eric Jeffrey Sherman
Memorial Sloan-Kettering Cancer Center, New York, NY
Eric Jeffrey Sherman , Alan Loh Ho , Matthew G. Fury , Shrujal S. Baxi , Sofia Haque , Brynna Lane Lipson , Sarah Kurz , James A. Fagin , David G. Pfister
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT01141309
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6024)
DOI
10.1200/jco.2013.31.15_suppl.6024
Abstract #
6024
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study.
First Author: Eric Jeffrey Sherman
Poster
2012 ASCO Annual Meeting
A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.
First Author: Eric Jeffrey Sherman
Poster
2021 ASCO Annual Meeting
Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.
First Author: Matthew H. Taylor
Poster
2017 ASCO Annual Meeting
Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
First Author: Bernard Tawfik